Reivindicaciones

1. 35 CLAIMS 1. Cell line characterized by comprising the fusion gene [ SEPT6-ABL2 ] within its genetic material, or the fusion transcript [SEPT6-ABL2], deposited at the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) with deposit number DSM ACC3372. 2. Cell line, according to claim 1, characterized by comprising the translocation t(X,l) (q24; q25.2) that fuses the genes [SEPT6-ABL2\. 3. Cell line, according to any of the previous claims, characterized by further comprising, within its genetic material, the deletion in 9p21.3 involving the gene CDKN2A , a rearrangement of TRB and/or the trisomy of chromosome 17. 4. Cell suspension comprising at least 80% of the cells according to any of the claims claim 1 to 3. 5. In vitro method for the diagnosis of T-ALL which comprises assessing the presence of the fusion gene or fusion transcript [SEPT6-ABL2] in a biological sample obtained from the patient, wherein the presence of the fusion gene or fusion transcript \SEPT6-ABL2] is indicative that the subject may be suffering from T-ALL. 6. In vitro method, according to claim 5, which further comprises determining the presence of the deletion in 9p21.3 involving CDKN2A , a rearrangement of TRB and/or the trisomy of chromosome 17 in a biological sample obtained from a patient. 7. In vitro method for subtyping T-ALL patients which comprises assessing the presence of the fusion gene or fusion transcript [SEPT6-ABL2] in a biological sample obtained from the patient, wherein the presence of the fusion gene or fusion transcript [SEPT 6- ABL2 ] is indicative that the subject may be suffering from T-ALL. 8. In vitro method, according to claim 7, which further comprises determining the presence of the deletion in 9p21.3 involving CDKN2A, a rearrangement of TRB and/or the trisomy of chromosome 17 in a biological sample obtained from a patient. 9. In vitro method, according to any of the claims 5 to 8, wherein the biological sample is blood or bone marrow. 10. In vitro use of the fusion gene or fusion transcript [SEPT6-ABL2] for the diagnosis of T-ALL. 11. In vitro use of the fusion gene or fusion transcript [ SEPT6-ABL2 ], according to claim 10, in combination with the use of the deletion in 9p21.3 involving the gene CDKN2A , a rearrangement of TRB and/or the trisomy of chromosome 17. 36 12. In vitro use of the fusion gene or fusion transcript [SEPT6-ABL2\ for subtyping T-ALL patients. 13 In vitro use of the fusion gene or fusion transcript [ SEPT6-ABL2 ], according to claim 12, in combination with the use of the deletion in 9p21.3 involving the gene CDKN2A , a rearrangement of TRB and/or the trisomy of chromosome 17. 14. Inhibitor of \SEPT6-ABL2 ], or of the signal induced thereof, selected from the group comprising: Tyrosine kinase inhibitor, PIM kinase inhibitor, or mTOR kinase inhibitor, or combinations thereof, for use in the treatment of T-ALL patients, wherein the patients are characterized by the presence of the fusion gene or fusion transcript [SEPT6-ABL2] 15. Inhibitor of [ SEPT6-ABL2 ], or of the signal induced thereof, selected from the group comprising: Tyrosine kinase inhibitor, PIM kinase inhibitor, or mTOR kinase inhibitor, or combinations thereof, for use, according to claim 14, in the treatment of T-ALL patients, wherein the patients are characterized by the presence of the fusion gene or fusion transcript [SEPT6-ABL2], in combination with deletion in 9p21.3 involving CDKN2A, and a rearrangement of TRB and/or the trisomy of chromosome 17. 16. Inhibitor of [SEPT6-ABL2], or of the signal induced thereof, for use according to any of the claims 14 or 15, wherein the Tyrosine kinase inhibitor is selected from: Brigatinib, Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib or Regorafenib, the PIM kinase inhibitor is PIM447, and the mTOR kinase inhibitor is Rampamycin.